PR Newswire Clinical TrialsOriginal article
AQUAPASS Completes Enrollment in REFORM-HF Pivotal Trial, Results to Be Presented at Major Heart Failure Conference This Fall
Data ReadoutAQUAPASS therapyPositive
AI Analysis
Summary
AQUAPASS announced completion of enrollment in the REFORM-HF pivotal trial for its noninvasive kidney-independent therapy for fluid overload in heart failure patients. Trial results are expected to be presented at a major heart failure conference in fall 2026.
Clinical Trial Data
Phase
pivotal
Outcome Details
Enrollment completion in REFORM-HF pivotal trial; results to be presented at major heart failure conference
Importance:6/10
Sentiment:
0.60
clinical trialenrollment completionheart failurekidney diseasedata readoutconference presentation
Read the original article
Published by PR Newswire Clinical Trials on August 10, 2026 1:40 PM